facebook
Subscribe50$/product give away!


Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

BUPRENORPHINE AND NALOXONE tablet


  1. Important:
  2. What Is The Most Important Information I Should Know About Buprenorphine And Naloxone Sublingual Tablets?
  3. What Are Buprenorphine And Naloxone Sublingual Tablets?
  4. Who Should Not Take Buprenorphine And Naloxone Sublingual Tablets?
  5. What Should I Tell My Doctor Before Taking Buprenorphine And Naloxone Sublingual Tablets?buprenorphine And Naloxone Sublingual Tablets May Not Be Right For You. Before Taking Buprenorphine And Naloxone Sublingual Tablets, Tell Your Doctor If You:
  6. Always Take Buprenorphine And Naloxone Sublingual Tablets Exactly As Your Doctor Tells You. Your Doctor May Change Your Dose After Buprenorphine And Naloxone Sublingual Tablets Can Cause Serious Side Effects Including:
  7. How Should I Dispose Of Unused Buprenorphine And Naloxone Sublingual Tablets?
  8. Active Ingredients:
  9. Inactive Ingredients:
  10. Patient Information

Important: 

Keep buprenorphine and naloxone sublingual tablets in a secure place away from children. Accidental use by a child is a medical emergency and can result in death. If a child accidentally uses buprenorphine and naloxone sublingual tablets, get emergency help right away.


Read this Medication Guide that comes with buprenorphine and naloxone sublingual tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor. Talk to your doctor or pharmacist if you have questions about buprenorphine and naloxone sublingual tablets.

Share the important information in this Medication Guide with members of your household.

What Is The Most Important Information I Should Know About Buprenorphine And Naloxone Sublingual Tablets? 

  • Buprenorphine and naloxone sublingual tablets can cause serious and life-threatening breathing problems. Call your doctor right away or get emergency help if:
    • You feel faint, dizzy, or confused
    • Your breathing gets much slower than is normal for you

These can be signs of an overdose or other serious problems.


  • Do not switch from buprenorphine and naloxone sublingual tablets to other medicines that contain buprenorphine without talking with your doctor. The amount of buprenorphine in a dose of buprenorphine and naloxone sublingual tablets may not be the same as the amount of buprenorphine in other medicines that contain buprenorphine. Your doctor will prescribe a starting dose of buprenorphine and naloxone sublingual tablets that may be different than other buprenorphine containing medicines you may have been taking.
  • Buprenorphine and naloxone sublingual tablets contain an opioid that can cause physical dependence.
  • Do not stop taking buprenorphine and naloxone sublingual tablets without talking to your doctor. You could become sick with uncomfortable withdrawal signs and symptoms because your body has become used to this medicine
  • Physical dependence is not the same as drug addiction
  • Buprenorphine and naloxone sublingual tablets are not for occasional or as needed use
  • An overdose, and even death, can happen if you take benzodiazepines, sedatives, antidepressants, tranquilizers, or alcohol while using buprenorphine and naloxone sublingual tablets. Ask your doctor what you should do if you are taking one of these.
  • Call a doctor or get emergency help right away if you:
    • Feel sleepy and uncoordinated
    • Have blurred vision
    • Have slurred speech
    • Cannot think well or clearly
    • Have slowed reflexes and breathing
  • Do not inject ( shoot-up ) buprenorphine and naloxone sublingual tablets.
    • Injecting buprenorphine and naloxone sublingual tablets may cause life-threatening infections and other serious health problems.
    • Injecting buprenorphine and naloxone sublingual tablets may cause serious withdrawal symptoms such as pain, cramps, vomiting, diarrhea, anxiety, sleep problems, and cravings.
  • In an emergency, have family members tell the emergency department staff that you are physically dependent on an opioid and are being treated with buprenorphine and naloxone sublingual tablets.
  • Never give anyone else your buprenorphine and naloxone sublingual tablets. They could die from taking it. Selling or giving away buprenorphine and naloxone sublingual tablets is against the law.
  • Store buprenorphine and naloxone sublingual tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.

What Are Buprenorphine And Naloxone Sublingual Tablets? 

Buprenorphine and naloxone sublingual tablets are a prescription medicine used to treat adults who are addicted to (dependent on) opioid drugs (either prescription or illegal) as part of a complete treatment program that also includes counseling and behavioral therapy.


Buprenorphine and naloxone sublingual tablets are a controlled substance (CIII) because it contains buprenorphine, which can be a target for people who abuse prescription medicines or street drugs. Keep your buprenorphine and naloxone sublingual tablets in a safe place to protect it from theft. Never give your buprenorphine and naloxone sublingual tablets to anyone else; it can cause death or harm them. Selling or giving away this medicine is against the law.


It is not known if buprenorphine and naloxone sublingual tablets are safe or effective in children.

Who Should Not Take Buprenorphine And Naloxone Sublingual Tablets? 

Do not take buprenorphine and naloxone sublingual tablets if you are allergic to buprenorphine or naloxone.

What Should I Tell My Doctor Before Taking Buprenorphine And Naloxone Sublingual Tablets?buprenorphine And Naloxone Sublingual Tablets May Not Be Right For You. Before Taking Buprenorphine And Naloxone Sublingual Tablets, Tell Your Doctor If You: 


Have trouble breathing or lung problems
Have an enlarged prostate gland (men)
Have a head injury or brain problem
Have problems urinating
Have a curve in your spine that affects your breathing
Have liver or kidney problems
Have gallbladder problems
Have adrenal gland problems
Have Addison's disease
Have low thyroid (hypothyroidism)
Have a history of alcoholism
Have mental problems such as hallucinations (

Always Take Buprenorphine And Naloxone Sublingual Tablets Exactly As Your Doctor Tells You. Your Doctor May Change Your Dose After Buprenorphine And Naloxone Sublingual Tablets Can Cause Serious Side Effects Including: 


Store buprenorphine and naloxone sublingual tablets at 20 to 25 C (68 to 77 F); excursions permitted between 15 and 30 C (59 and 86 F).
Keep buprenorphine and naloxone sublingual tablets in a safe place, out of the sight and reach of children

How Should I Dispose Of Unused Buprenorphine And Naloxone Sublingual Tablets? 

Dispose of unused buprenorphine and naloxone sublingual tablets as soon as you no longer need them.
Unused tablets should be flushed down the toilet.

General information about the safe and effective use of buprenorphine and naloxone sublingual tablets.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take buprenorphine and naloxone sublingual tablets for a condition for which it was not prescribed. Do not give buprenorphine and naloxone sublingual tablets to other people, even if they have the same symptoms you have. It may harm them and it is against the law.


This Medication Guide summarizes the most important information about buprenorphine and naloxone sublingual tablets. If you would like more information, talk to your doctor or pharmacist. You can ask your doctor or pharmacist for information that is written for health professionals. For more information call 1-800-818-4555.

Active Ingredients: 

buprenorphine and naloxone

Inactive Ingredients: 

lactose monohydrate, mannitol, povidone, anhydrous citric acid, sodium citrate, FD&C Yellow No.6 color, butylated hydroxyanisole, corn starch, pregelatinized starch, magnesium stearate, acesulfame potassium sweetener and a lemon / lime flavor

This Medication Guide has been approved by the U.S. Food and Drug Administration.


Distributed by:
Sun Pharmaceutical Industries, Inc.
Cranbury, NJ 08512


Manufactured by:
Sun Pharmaceutical Industries Ltd.
Survey No. 259/15,
Dadra-396 191, (U.T. of D & NH), India.

ISS. 05/2019
PGPI0192D

Patient Information 

Advise patients to read the FDA-approved patient labeling (Medication Guide)

Storage and Disposal

Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store buprenorphine and naloxone sublingual tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home[see Warnings and Precautions (5.1, 5.4), Abuse (9.2)].Inform patients that leaving buprenorphine and naloxone sublingual tablets unsecured can pose a deadly risk to others in the home.

Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly. Expired, unwanted, or unused buprenorphine and naloxone sublingual tablets should be disposed of by flushing the unused medication down the toilet if a drug take-back option is not readily available. Inform patients that they can visit www.fda.gov/drugdisposal for a complete list of medicines recommended for disposal by flushing, as well as additional information on disposal of unused medicines.

Safe Use


Before initiating treatment with buprenorphine and naloxone sublingual tablets, explain the points listed below to caregivers and patients. Instruct patients to read the Medication Guide each time buprenorphine and naloxone sublingual tablet is dispensed because new information may be available.



  • Buprenorphine and naloxone sublingual tablet must be administered whole. Advise patients not to cut, chew, or swallow buprenorphine and naloxone sublingual tablet.
  • Inform patients and caregivers that potentially fatal additive effects may occur if buprenorphine and naloxone sublingual tablet is used with benzodiazepines or other CNS depressants, including alcohol. Counsel patients that such medications should not be used concomitantly unless supervised by ahealthcare provider.[see Warnings and Precautions (5.2), (5.3), Drug Interactions (7)].
  • Advise patients that buprenorphine and naloxone sublingual tablets contain an opioid that can be a target for people who abuse prescription medications or street drugs, to keep their tablets in a safe place, and to protect them from theft.
  • Instruct patients to keep buprenorphine and naloxone sublingual tablets in a secure place, out of the sight and reach of children. Accidental or deliberate ingestion by a child may cause respiratory depression that can result in death. Advise patients to seek medical attention immediately if a child is exposed to buprenorphine and naloxone sublingual tablets.
  • Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform theirhealthcare providersif they are taking, or plan to take serotonergic medications[see Drug Interactions (7)].
  • Inform patients that opioids could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms[see Warnings and Precautions (5.6)].
  • Advise patients to never give buprenorphine and naloxone sublingual tablets to anyone else, even if he or she has the same signs and symptoms. It may cause harm or death.
  • Advise patients that selling or giving away this medication is against the law.
  • Caution patients that buprenorphine and naloxone sublingual tablets may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving or operating machinery. Caution should be taken especially during drug induction and dose adjustment and until individuals are reasonably certain that buprenorphine therapy does not adversely affect their ability to engage in such activities.[see Warnings and Precautions (5.13)]
  • Advise patients not to change the dosage of buprenorphine and naloxone sublingual tablets without consulting theirhealthcare provider.
  • Advise patients that if they miss a dose of buprenorphine and naloxone sublingual tablet they should take it as soon as they remember. If it is almost time for the next dose, they should skip the missed dose and take the next dose at the regular time.
  • Advise patients to take buprenorphine and naloxone sublingual tablets once a day.
  • Inform patients that buprenorphine and naloxone sublingual tablets can cause drug dependence and that withdrawal signs and symptoms may occur when the medication is discontinued.
  • Advise patients seeking to discontinue treatment with buprenorphine for opioid dependence to work closely with theirhealthcare provideron a tapering schedule and inform them of the potential to relapse to illicit drug use associated with discontinuation of opioid agonist/partial agonist medication-assisted treatment.
  • Advise patients that, like other opioids, buprenorphine and naloxone sublingual tablets may produce orthostatic hypotension in ambulatory individuals.[see Warnings and Precautions (5.14)]
  • Advise patients to inform theirhealthcare providerif any other prescription medications, over-the-counter medications, or herbal preparations are prescribed or currently being used.[see Drug Interactions (7)]
  • Advise women that if they are pregnant while being treated with buprenorphine and naloxone sublingual tablet, the baby may have signs of withdrawal at birth and that withdrawal is treatable.[see Warnings and Precautions (5.5), Use in Specific Populations (8.1)].
  • Advise women who are breastfeeding to monitor the infant for drowsiness and difficulty breathing.[see Use in Specific Populations (8.2)].
  • Inform patients that chronic use of opioids may cause reduced fertility. It is not known whether these effects on fertility are reversible[see Females and Males of Reproductive Potential (8.3)].
  • Advise patients to inform their family members that, in the event of emergency, the treatinghealthcare provideror emergency room staff should be informed that the patient is physically dependent on an opioid and that the patient is being treated with buprenorphine and naloxone sublingual tablets.



Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources
2017 © Copyright PharmacyHQ.com. Questions?
Please contact: pharmacyhq.mail@gmail.com